Borthwick Kathleen 4

What Happened

• Kathleen Borthwick, Chief Financial Officer of Passage BIO (PASG), was granted a derivative equity award on 2026-03-16 covering 15,610 shares. The filing reports an acquisition price of $0.00 (no cash paid at grant); the instrument is reported as a derivative (stock option/award).

Key Details

• Transaction date: 2026-03-16; Filing date: 2026-03-18 (filed two days after the transaction).
• Reported amount: 15,610 shares; price reported as $0.00; reported cash value at grant: $0.
• Vesting: the option/award vests 1/48 of the total shares monthly beginning April 16, 2026 until fully vested, subject to continued service (footnote F1).
• Post-transaction beneficial ownership: not specified in the provided excerpt.
• No indication in the excerpt of a 10b5-1 plan, cashless exercise, tax withholding, or late filing penalties.

Context

• This was a grant/award (compensation), not an open‑market purchase or sale. As a derivative award, the shares are not immediately transferable; value to the insider will depend on vesting and any exercise/strike terms (not detailed here). Grants like this are routine executive compensation and do not by themselves indicate a buy or sell signal.